Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers-Reference-Cited by-同舟云学术

Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers

Published:2020-02 Issue:1 Volume:20 Page:e65-e74
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Shui Ruohong,Liang Xizi,Li Xiaomei,Liu Yueping,Li Huixiang,Xu Enwei,Zhang Zhang,Lian Yuane,Guo Shuangping,Yao Min,Yang Hanjin,Xu Fangping,Liu Yiqiang,Liu Ju,Guo Deyu,Wang Kuansong,Li Jinfan,Ma Yun,Wang Jingmei,Shi Jie,Bu Hong,Yang Wentao

Funder

Science and Technology Commission of Shanghai Municipality

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. WHO Classification of Tumors of the Breast;Lakhani,2012

2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer;Hammond;J Oncol Pract,2010

3. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

4. Guideline for testing of estrogen and progesterone receptors in breast cancer;Zhonghua Bing Li Xue Za Zhi,2015

5. Guidelines for HER2 detection in breast cancer, the 2014 version;Zhonghua Bing Li Xue Za Zhi,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China;PeerJ;2024-05-29

2. Cu-MOF/Aptamer/Magnetic Bead Sensor for Detection of Breast Cancer Biomarkers HER2 and ER;ACS Applied Nano Materials;2024-04-12

3. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study;The Oncologist;2024-02-16

4. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation;Frontiers in Oncology;2024-01-25

5. Treatment Status and Research Progress of Breast Cancer with Low HER2 Expression;Advances in Clinical Medicine;2024